Foundation-Directed Therapeutic Development in Huntington鈥檚 Disease

详细信息    查看全文

• 作者：Celia Dominguez ; Ignacio Munoz-Sanjuan
• 刊名：Journal of Medicinal Chemistry
• 出版年：2014
• 出版时间：July 10, 2014
• 年：2014
• 卷：57
• 期：13
• 页码：5479-5488
• 全文大小：418K
• ISSN：1520-4804

文摘

Huntington鈥檚 disease (HD) is an autosomal dominant neurodegenerative disease that devastates patients and their families. It is caused by expansion of the CAG repeat in the huntingtin gene (HTT) and characterized pathologically by the loss of pyramidal neurons in several cortical areas, striatal medium spiny neurons, and hypothalamic neurons. Clinically, a distinguishing feature of the disease is uncontrolled involuntary movements (chorea) accompanied by progressive cognitive and psychiatric impairment. Currently there are no effective disease-modifying treatments for HD, although antidepressant and antipsychotic medications are typically utilized to manage HD symptoms, in addition to the only approved drug for the treatment of chorea in HD, tetrabenazine (TBZ). CHDI is a not-for-profit organization focused solely on HD. Herein we describe our foundation-directed therapeutic development efforts highlighting our collaborations and internal programs that are in various stages of development.